全國服務咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：Lisinopril dihydrate 83915-83-7描述Lisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
產品型號：abs47027255廠商性質：生產廠家更新時間：2025-12-03訪 問 量：809產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 83915-83-7 |
|---|---|---|---|
| 分子式 | C21H35N3O7 | 純度 | 99% |
| 分子量 | 441.52 | 貨號 | abs4702725 |
| 規(guī)格 | 500mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | used in treatment of hypertension | 應用領域 | 化工,生物產業(yè),農林牧漁,制藥/生物制藥,綜合 |
Lisinopril dihydrate 83915-83-7
| 產品描述 | |
| 描述 | Lisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks. |
| 純度 | 99% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 賴諾pu利二水合物 |
| 可溶性/溶解性 | H2O : 33.33 mg/mL (75.49 mM; Need ultrasonic) DMSO : 1 mg/mL (2.26 mM; Need ultrasonic) |
| 生物活性 | |
| 靶點 | ACE |
| In vitro(體外研究) | Lisinopril significantly reduces left ventricular (LV) end-diastolic pressure (EDP), pulmonary capillary wedge pressure (PCWP) and end-diastolic stress, addition of atenolol to Lisinopril further reduces EDP and PCWP. Lisinopril is a structural homologue of enalaprilat, differing only in the second amino acid side chain. Lisinopril inhibits Angiotensin-converting enzyme (ACE) in vitro, as well as after parenteral and oral administration to humans; its oral bioavailability is only 25-29%, but it has a longer duration of action than enalapril. |
| In vivo(體內研究) | Lisinopril treated SHR rats has significantly raised total cholesterol levels compared to untreated spontaneously hypertensive rats (SHR) rats (+27%), but not compared to lisinopril treated Wistar Kyoto rats (WKY) rats. Lisinopril is a long-acting angiotensin-converting enzyme inhibitor which blocks the renin-angiotensin system (RAS) and reduces systemic blood pressure in rats. Lisinopril reduces the hydroxyproline level and inhibits accumulation of collagens in the pulmonary tissue of the treatment group (paraquat + lisinopril) and per-treatment group (lisinopril + paraquat) in rats. Lisinopril results in preserved ultrafiltration volume (UF), glucose reabsorption (D 1 /D 0 glucose) and peritoneal thickness in rats. Lisinopril (0.2 mg/kg twice a day for 10 days) protects the cell membrane integrity and lessens free radical-induced oxidant stress in guinea pig hearts. |
| 研究領域 | |
| 研究領域 | NeuroscienceEndocrine system Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：